Home   Business   Article

Subscribe Now

CN Bio’s organ-on-a-chip platform named Top 10 Innovation of 2021

More news, no ads


CN Bio’s organ-on-a-chip platform has been recognised as a Top 10 Innovation of 2021 by The Scientist.

The Cambridge Science Park company designs and manufactures single- and multi-organ microphysiological systems (MPS) which help to provide insights into the potential effects of novel therapeutics - offering an alternative to using animal models.

From left, David Hughes and Patrick Driscoll, of CN Bio. Picture: Keith Heppell
From left, David Hughes and Patrick Driscoll, of CN Bio. Picture: Keith Heppell

Its PhysioMimix Multi-Organ MPS was second in the list from industry publication, which publishes an annual list of innovations that its judges predict will have the biggest impact in advancing scientific understanding or addressing life science challenges.

CN Bio believes its system could play a key role in addressing the inefficiency inherent in usual drug discovery processes. Only one in 10 candidates in phase I trials reach market approval, underling the desperate need for better tools to predict clinical success.

Dr David Hughes, CEO of CN Bio, said: “It is an honour for our PhysioMimix Multi-Organ system to be recognised by The Scientist in its 2021 list of Top 10 Innovations.

“Translating findings to in vivo settings remains a challenge due to cross-species differences and insufficient understanding of human pathophysiology.

“We developed the multi-organ system to address these drug development bottlenecks: to decrease the risk of clinical failures due to cross-species differences whilst enabling the development of new human-specific modalities where animal models are less suited.

“We look forward to 2022 as we continue to expand our technology portfolio and its applications within humanised pre-clinical research.”

CN Bio’s PhysioMimix
CN Bio’s PhysioMimix

The PhysioMimix Multi-Organ system builds on CN Bio’s single organ-on-a-chip solutions. It enables researchers to recreate complex human inter-organ communication and systemic effects in a multi-well format.

The system is the only platform on the market that can perform both single- and multi-organ experiments.

The latter enables the company’s in vitro 3D liver model to be combined with a range of other organ models such as gut, lung or kidney via fluidic flow. This is designed to recapitulate human physiology in the laboratory.

By Interconnecting these lab-grown organs, researchers can simulate processes such as drug absorption and metabolism, or understand interactions between organs that drive disease or cause unexpected toxicities.

The organ models mimic functions and drug response.

The launch of the system in March, which built on 10 years of research, is a milestone in CN Bio’s mission to develop a human ‘body-on-a-chip’.

Read more

Innovate UK grant to accelerate CN Bio’s Covid-19 research

CN Bio moves from organ-on-a-chip to human-on-a-chip

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More